KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early 2026 Company entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with up to $750 million in potential total payments Well-capitali ...

Exhibit 99.1 Village Farms International Delivers Record Profitability and Performance from Continuing Operations in Q2/25 Vancouver, August 11, 2025 – Village Farms International, Inc. ("Village Farms" or the "Company") (NASDAQ: VFF) today reported financial results for its second quarter ended June 30, 2025. All figures are in U.S. dollars unless otherwise indicated. The Company's second quarter 2025 results reflect the May 30, 2025 closing of its previously-announced, transformative transaction to privat ...

Exhibit 99.1 WeightWatchers Announces Second Quarter 2025 Results Successful completion of strategic reorganization, reducing debt by $1.15 billion. In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a "Successor" period from 6/25/25 to 6/30/25 Combined Revenues 1 of $189 million, down 6% vs. prior year; Combined Clinical Revenues 1 of $31 million, up 55% vs. prior year Predecessor Net Income 1 of $1,191 million and Net Margin1 of 673% were imp ...

- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 "We were also gratified to see that our V007 trial data was one of only three presentations selected for special mention by the Society of Vascular Surgery in June, and that the Society chose to highlight the strength of the results in their own announcement," continued Dr. Nik ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-40079 RUMBLE INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the reg ...

Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2025 Financial Results HOLLISTON, Mass., August 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2025. "We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first- hand the dedication of our team. The fundamentals of the business remain intact with attractive mar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-38783 VILLAGE FARMS INTERNATIONAL, INC. (Exact name of Registrant as Specified in its Charter) (State or other Jurisdiction of Inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delawa ...

[Corporate Update and Highlights](index=1&type=section&id=Compass%20Therapeutics%20Reports%202025%20Second%20Quarter%20Financial%20Results%20and%20Provides%20Corporate%20Update) Compass Therapeutics reported positive clinical trial updates for key pipeline candidates and maintained a strong cash position [CEO Statement and Overall Summary](index=1&type=section&id=CEO%20Statement%20and%20Overall%20Summary) Compass Therapeutics reported positive clinical trial updates for its key pipeline candidates, including tovecimig and CTX-8371, and ended the quarter with a strong cash position - The analysis for secondary endpoints (progression-free survival and overall survival) for the tovecimig Phase 2/3 trial is now guided for Q1 2026, delayed from original projections due to fewer deaths observed in the study[3](index=3&type=chunk) - The Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific) has shown two deep and confirmed partial responses, prompting the initiation of expansion cohorts in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) in Q4 2025[4](index=4&type=chunk) - Preclinical data for CTX-10726 (PD-1 x VEGF bispecific) suggests superiority to a leading candidate, ivonescimab, with an IND submission planned for Q4 2025[4](index=4&type=chunk) - The company's balance sheet remains strong, ending Q2 with **$101 million** in cash and marketable securities, which is expected to fund operations into 2027[4](index=4&type=chunk)[6](index=6&type=chunk)[17](index=17&type=chunk) [Development Pipeline Updates](index=1&type=section&id=Development%20Pipeline%20Updates) The company provided updates on its clinical pipeline, detailing progress for key candidates and anticipated milestones [Tovecimig (DLL4 and VEGF-A bispecific antibody)](index=1&type=section&id=Tovecimig%20(DLL4%20and%20VEGF-A%20bispecific%20antibody)) The Phase 2/3 COMPANION-002 study in biliary tract cancer (BTC) successfully met its primary endpoint of overall response rate, with secondary endpoint analysis rescheduled to Q1 2026 - In April 2025, the randomized Phase 2/3 COMPANION-002 study met its primary endpoint, showing tovecimig plus paclitaxel significantly improved overall response rate compared to paclitaxel alone in BTC patients[5](index=5&type=chunk) - The analysis of secondary endpoints, including Overall Survival (OS) and Progression-Free Survival (PFS), is now expected in Q1 2026 because the pre-specified number of deaths (80% pooled mortality) has not yet been reached[3](index=3&type=chunk)[6](index=6&type=chunk)[11](index=11&type=chunk) - A Phase 2 basket study of tovecimig in a broader set of DLL4+ cancers (e.g., gastric, ovarian, renal) is expected to begin following the secondary endpoint data analysis from the COMPANION-002 trial[11](index=11&type=chunk) [CTX-8371 (PD-1 x PD-L1 bispecific antibody)](index=2&type=section&id=CTX-8371%20(PD-1%20x%20PD-L1%20bispecific%20antibody)) The Phase 1 dose-escalation study demonstrated significant anti-tumor activity, leading to planned expansion cohorts in NSCLC and TNBC in Q4 2025 - Two deep partial responses were observed in the first four dosing cohorts (n=12): a **100% reduction** in target lesions for an NSCLC patient and a **>90% reduction** for a TNBC patient[4](index=4&type=chunk)[6](index=6&type=chunk)[11](index=11&type=chunk) - Expansion cohorts focusing on NSCLC and TNBC are planned to initiate in Q4 2025[4](index=4&type=chunk)[11](index=11&type=chunk) - Detailed results from the Phase 1 dose-escalation study are expected to be reported at a medical meeting in Q4 2025, with data from the cohort expansion stage anticipated in 2026[11](index=11&type=chunk) [CTX-10726 (PD-1 x VEGF-A bispecific antibody)](index=2&type=section&id=CTX-10726%20(PD-1%20x%20VEGF-A%20bispecific%20antibody)) Preclinical data indicates CTX-10726 is superior to ivonescimab, with an Investigational New Drug (IND) application planned for Q4 2025 - Demonstrated superior tumor control and PD-1 inhibition compared to ivonescimab in head-to-head preclinical studies[4](index=4&type=chunk)[11](index=11&type=chunk) - An IND submission for CTX-10726 is expected in Q4 2025, with initial clinical data anticipated in 2026[6](index=6&type=chunk)[11](index=11&type=chunk) - CTX-10726 was discovered in-house and leverages Compass's expertise in bispecific antibody drug development, including manufacturing processes which are already at commercially viable yields[4](index=4&type=chunk) [CTX-471 (CD137 agonist antibody)](index=2&type=section&id=CTX-471%20(CD137%20agonist%20antibody)) Compass plans to initiate a Phase 2 trial for CTX-471, a CD137 agonist antibody, in the second half of 2025 - A Phase 2 trial of CTX-471 is expected to be initiated in the second half of 2025[11](index=11&type=chunk) - The trial will enroll patients with tumors expressing NCAM (CD56)[11](index=11&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Compass Therapeutics reported increased net losses in Q2 and H1 2025 due to higher R&D expenses, with cash sufficient into 2027 [Second Quarter 2025 Financial Performance](index=3&type=section&id=Second%20Quarter%202025%20Financial%20Performance) For the second quarter of 2025, Compass reported an increased net loss of **$19.9 million** ($0.14 per share), primarily driven by higher R&D expenses Net Loss Overview | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Loss** | $19.9M | $13.1M | $36.5M | $23.9M | | **Net Loss per Share** | $0.14 | $0.10 | $0.26 | $0.17 | [Operating Expenses](index=3&type=section&id=Operating%20Expenses) Total operating expenses increased in Q2 and the first six months of 2025 compared to the prior year, driven by higher R&D costs [Research and Development (R&D) Expenses](index=3&type=section&id=Research%20and%20Development%20(R%26D)%20Expenses) R&D expenses rose by **47%** to **$16.4 million** in Q2 2025, primarily due to increased manufacturing costs for clinical trial materials R&D Expense Summary | Period | R&D Expense | Prior Year Period | % Change | | :--- | :--- | :--- | :--- | | Q2 2025 | $16.4M | $11.2M | +47% | | H1 2025 | $29.5M | $20.7M | +42% | - The increase was primarily attributable to additional manufacturing expenses for tovecimig and CTX-10726[13](index=13&type=chunk) [General and Administrative (G&A) Expenses](index=3&type=section&id=General%20and%20Administrative%20(G%26A)%20Expenses) G&A expenses remained flat at **$4.7 million** for Q2 2025 but increased by **20%** for the first six months due to higher share-based compensation G&A Expense Summary | Period | G&A Expense | Prior Year Period | % Change | | :--- | :--- | :--- | :--- | | Q2 2025 | $4.7M | $4.7M | 0% | | H1 2025 | $9.6M | $8.0M | +20% | [Cash Position and Runway](index=3&type=section&id=Cash%20Position) As of June 30, 2025, Compass held **$101 million** in cash and marketable securities, expected to fund operations into 2027 Cash and Marketable Securities | Date | Cash & Marketable Securities | | :--- | :--- | | June 30, 2025 | $101.0M | | Dec 31, 2024 | $126.7M | - The current cash position provides an anticipated cash runway into 2027[4](index=4&type=chunk)[17](index=17&type=chunk) - During the first six months of 2025, **$25 million** of net cash was used in operating activities[17](index=17&type=chunk)

The Company reported net income of $11.0 million, a decrease of 21.4%. Diluted earnings per share were $0.37, a decrease of 11.9%. The decreases in net income and diluted earnings per share were impacted by the revenue items noted above, as well as transaction costs of $2.2 million and higher amortization expense from past M&A activity. The decrease in revenue was partially offset by lower service charges from agents and banks. Diluted earnings per share was positively impacted by the reduction in share cou ...